During a press conference Tuesday at the International AIDS Conference in Vienna, Anthony Fauci, MD, Director of the National Institute of Allergy and Infectious Diseases at NIH, describes the Vaginal and Oral Interventions to Control the Epidemic (VOICE) trial. The study is testing the safety and efficacy of microbicide gel containing the ARV drug tenofovir, and oral tablets containing tenofovir or a combination of tenofovir and emtricitabine known by the brand name Truvada.
Amid unprecedented challenges to routine healthcare access, trial results mark a first for a critically needed HIV prevention measure An investigational drug administered by injection every […]
In the six weeks before South Africa responded its first diagnoses of COVID-19 with the start of physical distancing measures, more than 47,000 people on average […]
What we have learned from HIV can guide responses to COVID-19 that are innovative, effective and inclusive, and can help end the pandemic faster The following […]
The following is a guest post by Kenneth G. Castro, MD, FIDSA Since its formation in 1948, WHO has relied heavily on the U.S. for collaborations […]